Stent having non-woven framework containing cells

• US 6,913,762 B2
• Filed: 04/25/2001
• Issued: 07/05/2005
• Est. Priority Date: 04/25/2001
• Status: Expired due to Term

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Berry, David, Simari, Robert D., Caplice, Noel, Schwartz, Robert S., Holmes, David R. Jr.
• Primary Examiner(s): Naff, David M.
• Application Number:
  US09/843,295
• Publication Number:
  US 20020160033A1
• Time in Patent Office: 1,532 Days
• Field of Search: 435/176, 435/177, 435/180, 435/283.1, 435/395, 435/398, 435/402, 424/423, 424/93.7
• US Class Current: 424/423
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: B33Y 80/00 Products made by additive manufacturing

Abstract

Implantable medical devices that include a non-woven framework are described, as well as methods of using such devices to deliver therapeutic compounds to a patient.

Claims

1. An implantable medical device comprising a stent, a non-woven framework attached to said stent, and in vitro seeded cells within said non-woven framework, wherein said non-woven framework comprises stainless steel fibers and pores having an average size of at least 40 μ

m, wherein said non-woven framework is not coated with an extracellular matrix protein, and wherein said implantable medical device is implantable within the vascular system of a mammal via percutaneous deployment.

2. The implantable medical device of claim 1, wherein said cells express a polypeptide selected from the group consisting of vascular endothelial growth factor, natriuretic peptide, prostacyclin synthase, angiostatin, endostatin, erythropoietin, and a marker polypeptide.

3. The implantable medical device of claim 1, wherein said stent is balloon expandable or self-expanding.